You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Inhibits glutamate release from presynaptic terminals and increases Na+-dependent glutamate uptake in rat cortical synaptosomes. Blocks voltage-dependent Na+ channels and inhibits GABA uptake by striatal synaptosomes. Also activates TRPC5 channels. Psychotropic agent with anticonvulsant, hypnotic, anxiolytic, anti-ischemic, anesthetic and neuroprotective properties.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.71||10 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 270.66. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.69 mL||18.47 mL||36.95 mL|
|5 mM||0.74 mL||3.69 mL||7.39 mL|
|10 mM||0.37 mL||1.85 mL||3.69 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References are publications that support the biological activity of the product.
Fumagalli et al (2008) Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur.J.Pharmacol. 578 171 PMID: 18036519
Song et al (1997) Differential action of Riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J.Pharmacol.Exp.Ther. 282 707 PMID: 9262334
Taylor and Meldrum (1995) Na+ channels as targets for neuroprotective drugs. TiPS 16 309 PMID: 7482996
Umeniya and Berger (1995) Inhibition by Riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones. Br.J.Pharmacol. 116 3227 PMID: 8719800
Richter et al (2014) Riluzole activates TRPC5 channels independently of PLC activity. Br.J.Pharmacol. 171 158 PMID: 24117252
If you know of a relevant reference for Riluzole hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Riluzole hydrochloride, Riluzole hydrochloride supplier, Glutamate, release, inhibitors, inhibits, GABA, uptake, Na+, channel, blockers, glutamate, mGlur, Receptors, Metabotropic, Sodium, NaV, Channels, voltage-gated, voltage-dependent, iGlu, Ionotropic, BGT-1, GAT, Transporters, Monoamine, Neurotransmitter, neuroprotective, TRPC5, canon, Miscellaneous, Voltage-gated, TRPC, 0768, Tocris Bioscience
11 Citations for Riluzole hydrochloride
Citations are publications that use Tocris products. Selected citations for Riluzole hydrochloride include:
Du et al (2015) Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat.Commun. 6 6626 PMID: 25806427
Dolfi et al (2017) R.zole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget 8 44639 PMID: 28591718
Du et al (2015) Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun 6 6626 PMID: 25806427
Veettil et al (2014) Glutamate secretion and metabotropic glutamate receptor 1 expression during Kaposi's sarcoma-associated herpesvirus infection promotes cell proliferation. PLoS Pathog 10 e1004389 PMID: 25299066
Viemari et al (2013) β-Noradrenergic receptor activation specifically modulates the generation of sighs in vivo and in vitro. Neurochem Int 7 179 PMID: 24273495
Carbone et al (2012) R.zole elevates GLT-1 activity and levels in striatal astrocytes. BMC Neurosci 60 42613 PMID: 22080156
Carbone et al (2012) R.zole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. Cells 13 38 PMID: 22480308
Morgado-Valle et al (2010) Glycinergic pacemaker neurons in preBötzinger complex of neonatal mouse. J Neurosci 30 3634 PMID: 20219997
Le et al (2010) The glutamate release inhibitor R.zole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 130 2240 PMID: 20505744
Rosenberg et al (2015) Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression. Front Neural Circuits 8 42614 PMID: 25749171
Park et al (2013) Slowly inactivating component of Na+ current in peri-somatic region of hippocampal CA1 pyramidal neurons. J Neurophysiol 109 1378 PMID: 23236005
Do you know of a great paper that uses Riluzole hydrochloride from Tocris? Please let us know.
Reviews for Riluzole hydrochloride
There are currently no reviews for this product. Be the first to review Riluzole hydrochloride and earn rewards!
Have you used Riluzole hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.